CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
about
Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapyChemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLCMolecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) projectHPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation.Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancerCHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.Aurora B expression modulates paclitaxel response in non-small cell lung cancer.Clinicopathological significance of CHFR methylation in non-small cell lung cancer: a systematic review and meta-analysis.Upregulation of the checkpoint protein CHFR is associated with tumor suppression in pancreatic cancers.The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
P2860
Q33727749-939F441F-4403-4507-AF83-613705F6BCF8Q34005272-4C5B0B83-F289-4E80-89C7-B8E5494340E0Q34168437-89382685-B81A-4561-8879-0041E015B1BFQ34183784-143E24FB-3BF7-4127-AE1C-841861E0EA00Q34778891-79CEA7B7-9C27-47CB-B515-9656463C81A0Q34998465-375DAE27-39B6-4572-A25D-85B6167BA959Q36544421-0BB43A5B-27F9-4B3E-9944-F6D4BE780704Q37315455-2D67A608-2B70-4DA1-85A5-56B840D7BF9BQ37705684-D6648EB9-8AE5-471E-90E3-17A10E5BEF5EQ38720934-A2017E59-B22C-493B-ABD6-E2FA22A654A6Q47193635-A8974A77-4826-4771-BEB3-A6D38D1E0674Q49413106-364D2271-7F2D-45BA-BD97-212B480FF71BQ49724590-D4EC33AF-764D-4411-83D5-BF452A30ED1E
P2860
CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
CHFR protein expression predic ...... e therapy in metastatic NSCLC.
@ast
CHFR protein expression predic ...... e therapy in metastatic NSCLC.
@en
type
label
CHFR protein expression predic ...... e therapy in metastatic NSCLC.
@ast
CHFR protein expression predic ...... e therapy in metastatic NSCLC.
@en
prefLabel
CHFR protein expression predic ...... e therapy in metastatic NSCLC.
@ast
CHFR protein expression predic ...... e therapy in metastatic NSCLC.
@en
P2093
P2860
P1476
CHFR protein expression predic ...... ne therapy in metastatic NSCLC
@en
P2093
Dacian Bonta
Dana C Nickleach
Fadlo R Khuri
Gabriel L Sica
James G Herman
Malcom V Brock
Maria J A Ribeiro
Rathi N Pillai
P2860
P304
P356
10.1158/1078-0432.CCR-12-2995
P407
P577
2013-02-05T00:00:00Z